Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
02 oct. 2023 12h53 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the entry...
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
21 sept. 2023 08h30 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 08h30 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
14 août 2023 16h15 HE
|
Checkpoint Therapeutics, Inc
Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024 Longer-term cosibelimab results...
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
31 juil. 2023 08h00 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it...
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
27 juil. 2023 07h00 HE
|
Checkpoint Therapeutics, Inc
55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate in metastatic cSCC Cosibelimab continues to demonstrate a...
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
28 juin 2023 08h00 HE
|
Checkpoint Therapeutics, Inc
Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date...
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Checkpoint Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims
27 avr. 2020 07h00 HE
|
Fields Kupka & Shukurov LLP
NEW YORK, April 27, 2020 (GLOBE NEWSWIRE) -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Checkpoint Therapeutics,...